Medical Oncologist
Stopping & survivorship
Drug Holidays: — Are Planned Breaks Safe?
The idea of stopping treatment — even briefly — is frightening for most people. It is also something more oncologists are discussing with certain patients, in specific cancers, under close monitoring. A drug holiday is not the same as giving up.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Not for every cancer — Planned breaks are studied and recognised mainly in a small number of cancer types where deep, sustained remission has been established.
- More monitoring, not less — A drug holiday usually means more frequent blood tests and scans — not fewer — to catch any change early.
- Different from stopping for side effects — A planned break is a deliberate, oncologist-led decision based on your response, not an unplanned stop due to toxicity.
- Treatment fatigue is real — Exhaustion from years on daily medication is a legitimate medical concern, and your oncologist needs to hear about it.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
A drug holiday is a planned, monitored break from cancer treatment. It is established for certain cancers — particularly some blood cancers where deep remission has been sustained. For most solid tumours and most patients, the evidence for planned breaks is limited. Whether one is appropriate for you depends on your cancer type, your depth of response, and your oncologist's assessment.
What is a drug holiday, and when does an oncologist consider one?
A drug holiday is a planned, closely monitored break from cancer medication. It is not the same as stopping because of side effects, running low on medication, or deciding on your own to take a pause.
The most established context is in chronic myeloid leukaemia, where patients who achieve a sustained, deep molecular response on TKI therapy may be offered a treatment-free interval as a formal goal of treatment. European LeukemiaNet and NCCN guidance recognises treatment-free remission as an appropriate aim for eligible patients.
For some immunotherapy regimens, completing a defined course and then stopping — rather than continuing indefinitely — is part of the protocol for certain indications. This is a different situation from an open-ended break.
For most solid tumours and most metastatic cancers, planned breaks outside a clinical trial are not an established practice. Your oncologist will tell you where your cancer sits in relation to that evidence.
What will my oncologist need to know before agreeing to a break?
- How deep your response isA surface-level response and a deep molecular remission are very different starting points. The depth of your response is the single most important factor.
- How long you have been in remissionDuration matters. A sustained response over time gives more confidence than a recent one.
- Your cancer type and its biologyTreatment-free intervals are established in some cancers and unstudied in others. Your cancer type sets the boundaries of what is known.
- Whether you can manage intensive monitoringMore frequent tests, not fewer, are required during a break. In blood cancers where breaks are established, monthly molecular testing is typical for the first year.
- What you would do if the cancer began to returnA plan for restarting quickly is part of any break plan. Your team needs to know you are willing and able to act fast.
- What is driving the questionTreatment fatigue, family planning, a specific life event, the cost of medication — each is a legitimate reason, and each may lead to a different answer.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What does monitoring look like during a planned break?
Monitoring during a treatment-free interval is more intensive than when you are on treatment, not less. In blood cancers where breaks are established, guidelines specify frequent molecular testing — often monthly for the first year.
The aim is to detect very early signs that the disease is becoming active again, while there is still time to restart treatment and regain the previous response.
You should be given specific thresholds that would trigger restarting — not a vague instruction to watch and see. Ask your team to write down what result means you restart, and by when.
What if the cancer starts coming back during a break?
In the cancers where treatment-free intervals are best studied, a large proportion of patients who relapse after stopping regain their previous response when they restart the same treatment.
This is one of the things that makes planned breaks possible in those cancers — relapse, while unwelcome, is not the same as losing the treatment option entirely.
In less-studied settings, the picture is less clear. Before agreeing to any break, ask your oncologist directly: if I relapse, is there good evidence I can regain my response, and how quickly would you act? That answer shapes whether a break is reasonable for you.
Did you know?
Treatment-free remission in chronic myeloid leukaemia is now a formal treatment goal in European LeukemiaNet and NCCN guidelines — the first time stopping a targeted cancer therapy has been built into a treatment pathway rather than treated as non-compliance.
The shift happened because long-term follow-up showed that many patients who relapsed after stopping could regain deep remission when they restarted.
Source: European LeukemiaNet Recommendations for CML; NCCN Guidelines for Chronic Myeloid Leukemia
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is it safe to take a break from my cancer medication?
It depends on which cancer you have and how deeply it is responding. For a small number of cancers — most clearly in chronic myeloid leukaemia and certain immunotherapy protocols — planned breaks under close monitoring are an established option. For most other cancers, the evidence is not there yet, and an unplanned or unsupervised break carries real risk. The question to ask is not whether breaks are safe in general, but whether there is evidence for a break in your specific situation.
Will the treatment still work if I restart after a break?
In the cancers where treatment-free intervals are best studied, a proportion of patients who relapse after stopping can regain their previous response by restarting the same treatment. This is part of what makes the break feasible in those settings. In less-studied cancers, we do not have reliable data to answer that question confidently, which is one reason breaks are not routinely offered outside those specific contexts. Ask your oncologist directly whether your treatment has evidence on restarting after a pause.
What is treatment-free remission, and does it mean the cancer is gone?
Treatment-free remission means your cancer remains at undetectable or very low levels after stopping therapy — but it does not mean the cancer will not return. Monitoring continues for exactly this reason. In chronic myeloid leukaemia, treatment-free remission is a recognised goal of therapy according to European LeukemiaNet and NCCN guidelines. In other cancers, the concept is still being studied, and we do not yet have good data on how durable it is for all patients or who is most likely to benefit from it.
I am exhausted by years on daily medication. Is that a reason to ask about a break?
Yes, and your team needs to know. Treatment fatigue — the physical and psychological exhaustion of long-term daily medication — is a real medical concern that affects quality of life, adherence, and mental health. Raising it is not the same as asking to stop treatment. It opens a conversation about what options exist for you and what the risks of each are. Hiding it from your team leads to worse outcomes than talking about it.
Can I take a break because the medication is too expensive to continue?
Cost is a real and important factor, and hiding it from your team leads to worse outcomes than raising it. If cost is making it difficult to stay on your treatment, your oncologist and the social worker or counsellor attached to your care team need to know. There are sometimes patient assistance programmes, generic alternatives, or treatment modifications that can help. An unplanned break taken silently because of cost is riskier than a direct conversation about it.
How do I ask my oncologist about a drug holiday without sounding like I want to give up?
Ask it as a question about the evidence, not as a decision already made. 'I have read about treatment-free intervals — does the evidence apply to my situation?' signals engagement, not withdrawal. If treatment fatigue, cost, or a specific life reason is part of what is driving the question, say that too. It helps your team give you an answer that addresses what you are actually asking, rather than a general response to a question you did not quite ask.